BAY 3389934 + Matching Placebo / Diluent
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sepsis Associated Disseminated Intravascular Coagulation (DIC)
Conditions
Sepsis Associated Disseminated Intravascular Coagulation (DIC)
Trial Timeline
Sep 22, 2025 → Jan 30, 2026
NCT ID
NCT07176728About BAY 3389934 + Matching Placebo / Diluent
BAY 3389934 + Matching Placebo / Diluent is a phase 1 stage product being developed by Bayer for Sepsis Associated Disseminated Intravascular Coagulation (DIC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07176728. Target conditions include Sepsis Associated Disseminated Intravascular Coagulation (DIC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07176728 | Phase 1 | Recruiting |
Competing Products
20 competing products in Sepsis Associated Disseminated Intravascular Coagulation (DIC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alkaline Phosphatase + Placebo | AM-Pharma | Phase 2 | 44 |
| Drotrecogin alfa (activated) | Eli Lilly | Phase 2 | 52 |
| Meropenem | Pfizer | Approved | 84 |
| Imipenem | Merck | Approved | 85 |
| Cefiderocol | Shionogi | Phase 1 | 33 |
| eritoran tetrasodium + Placebo | Eisai | Phase 3 | 77 |
| E5564 | Eisai | Phase 2 | 52 |
| Drotrecogin Alfa (Activated) + placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin Alfa (activated) | Eli Lilly | Approved | 85 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| sPLA2 Inhibitor | Eli Lilly | Phase 1/2 | 41 |
| Drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin | Eli Lilly | Approved | 85 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| AZD9773 (CytoFab) | AstraZeneca | Phase 2 | 52 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 52 |